AimIt has previously been shown that β-blocker therapy reduces QT dynamics in heart failure patients. The aim of this study was to demonstrate this improvement with the third-generation β-blocker, nebivolol.MethodsA total of 72 heart failure patients with systolic dysfunction were included in the study. Corrected QT (QTc) and QT dispersion (QTcd) were measured manually by two independent observers at baseline and after nebivolol use (5 mg/day) in the first and third months of follow up.ResultsBoth QTc and QTcd were found to be significantly reduced in the first (455.3 ± 26.7 vs 441.2 ± 25.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 58.2 ± 5.6 ms, p = 0.001 for QTcd) and third months (455.3 ± 26.7 vs 436.0 ± 28.7 ms, p < 0.001 for QTc, and 65.6 ± 5.3 vs 56.0 ± 6.2 ms, p < 0.001 for QTcd) compared with baseline values.ConclusionNebivolol was associated with improved QT dynamics in heart failure patients with systolic dysfunction.
Amyloidosis is a disease characterized by deposition of proteins in tissues and organs. When these fibril deposits disrupting organ function confine to a single organ system, it is ''localized amyloidosis''. We herein; present a patient undergoing surgery for laryngeal amyloidosis located in neck region; to provide recommendations regarding the anesthetic management and follow-up of these patients. We wanted to call attention to the recurrent nature of this disease and the possibility of life threatening conditions that should be kept in mind in order to take precautions on time.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.